HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Chaudhary, N. I. Articles by Park, J. E. Search for Related Content PubMed PubMed Citation Articles by Chaudhary, N. I. Articles by Park, J. E.

Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis

Depts of ¹ Pulmonary Research, and ² Chemical Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, ⁴ Dept of Pneumology, Medical Centre, University Hospital Freiburg, Germany. ³ Dept of Oncology Research, Boehringer Ingelheim Austria GmbH, Vienna, Austria.

CORRESPONDENCE: A. Schnapp, Dept of Pulmonary Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstraße 65, D-88937, Biberach an der Riss, Germany. Fax: 49 07351545148. E-mail: andreas.schnapp{at}bc.boehringer-ingelheim.com

Keywords: BIBF 1000, bleomycin, imatinib mesylate, lung fibrosis

Received: November 23, 2006
Accepted January 19, 2007

BIBF 1000 is a small molecule inhibitor targeting the receptor kinases of platelet-derived growth factor (PDGF), basic fibroblast growth factor and vascular endothelial growth factor, which have known roles in the pathogenesis of pulmonary fibrosis.

The anti-fibrotic potential of BIBF 1000 was determined in a rat model of bleomycin-induced lung fibrosis and in an ex vivo fibroblast differentiation assay. Rats exposed to a single intra-tracheal injection of bleomycin were treated with BIBF 1000 starting 10 days after bleomycin administration. To gauge for anti-fibrotic activity, collagen deposition and pro-fibrotic growth factor gene expression was analysed in isolated lungs. Furthermore, the activity of BIBF 1000 was compared with imatinib mesylate (combined PDGF receptor, c-kit and c-abl kinase inhibitor) and SB-431542 (transforming growth factor (TGF)-ß receptor I kinase inhibitor) in an ex vivo TGF-ß-driven fibroblast to myofibroblast differentiation assay, performed in primary human bronchial fibroblasts.

Treatment of rats with BIBF 1000 resulted in the attenuation of fibrosis as assessed by the reduction of collagen deposition and the inhibition of pro-fibrotic gene expression. In the cellular assay both SB-431542 and BIBF 1000 showed dose-dependent inhibition of TGF-ß-induced differentiation, whereas imatinib mesylate was inactive.

BIBF 1000, or related small molecules with a similar kinase inhibition profile, may represent a novel therapeutic approach for the treatment of idiopathic pulmonary fibrosis.

This article has been cited by other articles:

				F. Hilberg, G. J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, et al. BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy Cancer Res., June 15, 2008; 68(12): 4774 - 4782. [Abstract] [Full Text] [PDF]

				P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF]

				B. R. Gochuico, N. A. Avila, C. K. Chow, L. J. Novero, H.-P. Wu, P. Ren, S. D. MacDonald, W. D. Travis, M. P. Stylianou, and I. O. Rosas Progressive Preclinical Interstitial Lung Disease in Rheumatoid Arthritis Arch Intern Med, January 28, 2008; 168(2): 159 - 166. [Abstract] [Full Text] [PDF]